Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 10/20 | 0.55 |
| ▸ | GAA | P10253 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29764383 | 0.88 | GAA (0.57) | PKMGAAALDH1A1L3MBTL1NPC1 | |
| SCHEMBL27238588 | 0.88 | GAA (0.57) | PKMGAAALDH1A1L3MBTL1NPC1 | |
| SCHEMBL29764384 | 0.88 | GAA (0.57) | PKMGAAALDH1A1L3MBTL1NPC1 | |
| SCHEMBL29764359 | 0.87 | PKM (0.60) | PKMGAAALDH1A1L3MBTL1NPC1 | |
| SCHEMBL27238539 | 0.84 | PKM (0.40) | PKMGAAALDH1A1L3MBTL1NPC1 | |
| SCHEMBL29764466 | 0.84 | PKM (0.50) | PKMGAAALDH1A1L3MBTL1NPC1 | |
| SCHEMBL24762923 | 0.84 | PKM (0.50) | PKMGAAALDH1A1L3MBTL1NPC1 | |
| SCHEMBL27238499 | 0.84 | PKM (0.51) | PKMGAAALDH1A1L3MBTL1NPC1 | |
| SCHEMBL24762619 | 0.82 | HTR2A (0.45) | ALDH1A1NPC1KMT2ALMNA | |
| SCHEMBL29764350 | 0.81 | MAOA (0.48) | PKMGAAALDH1A1L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2024-06-13 | — | — | US | disclosed |
| WO-2022169755-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| WO-2022169755-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | PACSIN2, TPX2, PRSS12 | PKM 4012/4885GAA 798/4885ALDH1A1 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.